Hu C. et al. (2018) further confirmed these findings, reporting a median OS of 13.6 months for patients with mutations in the six genes associated with pancreatic cancer (CDKN2A, TP53, MLH1, ATM, BRCA1, and BRCA2), compared to 11.4 months for patients without mutations [17]. This evidence concerns the gene TP53 and pancreatic neoplasm.